Friday, 17 March 2017

AstraZeneca receives fresh blow to potassium drug

LONDON (Reuters) - AstraZeneca said on Friday that U.S. regulators had rejected the British company's new drug for high potassium levels, in the latest setback to the product.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)